Connect with us

Life Sciences

Lunit, CARPL.ai Partner to Accelerate AI-Powered Medical Imaging

What You Should Know: – Lunit signed a global distribution agreement to provide its AI-based radiology solutions for clinical use via CARPL.ai’s platform….

Published

on

This article was originally published by HIT Consultant

What You Should Know:

Lunit signed a global distribution agreement to provide its AI-based radiology solutions for clinical use via CARPL.ai’s platform. Lunit is a South Korean-based AI software company devoted to developing AI solutions for precision diagnostics and treatment support, mainly focused on conquering cancer.

– The partnership will deliver Lunit INSIGHT CXR and Lunit INSIGHT MMG for commercial use in the U.S., Australia, Brazil, India, and Singapore.

CARPL Background

CARPL is an end-to-end technology platform for the development, validation, and deployment of medical imaging AI applications in clinical workflows. Used by some of the world’s top AI researchers and health systems, it provides a unique platform connecting picture archiving and communication systems (PACS) in clinical settings with third-party AI applications. Through CARPL’s interface, healthcare providers can seamlessly access Lunit’s AI solution suite for radiology, thereby improving access, affordability, and quality of medical care globally.

diagnostics



Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending